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ABSTRACT: Pharmaceutical scientists are increasingly interested
in amorphous drug formulations especially because of their higher
dissolution rates. Consequently, the thorough characterization and
analysis of these formulations are becoming more and more
important for the pharmaceutical industry. Here, fluorescence-
lifetime-imaging microscopy (FLIM) was used to monitor the
crystallization of an amorphous pharmaceutical compound,
indomethacin. Initially, we identified different solid indomethacin forms, amorphous and γ- and α-crystalline, on the basis of
their time-resolved fluorescence. All of the studied indomethacin forms showed biexponential decays with characteristic
fluorescence lifetimes and amplitudes. Using this information, the crystallization of amorphous indomethacin upon storage in 60
°C was monitored for 10 days with FLIM. The progress of crystallization was detected as lifetime changes both in the FLIM
images and in the fluorescence-decay curves extracted from the images. The fluorescence-lifetime amplitudes were used for
quantitative analysis of the crystallization process. We also demonstrated that the fluorescence-lifetime distribution of the sample
changed during crystallization, and when the sample was not moved between measuring times, the lifetime distribution could also
be used for the analysis of the reaction kinetics. Our results clearly show that FLIM is a sensitive and nondestructive method for
monitoring solid-state transformations on the surfaces of fluorescent samples.
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■ INTRODUCTION
Poor water solubility and dissolution are major challenges in
drug development. Most new drug candidates exhibit such
behavior, which may result in poor oral bioavailability. A
promising approach to solve this challenge is to utilize a drug’s
amorphous form, which lacks long-range molecular order and
has different properties compared with its crystalline counter-
parts, including higher water solubility and a higher dissolution
rate.1,2 Unfortunately, the amorphous form is unstable and
tends to crystallize into more stable crystalline forms. The
crystallization can occur during the mechanical processing of
the pharmaceutical product,3 during storage,4,5 or during
dissolution.6 The rate of crystallization depends on several
factors, such as the method used to prepare the amorphous
form,6,7 the surface areas of the crystallizing particles,8 and the
storage conditions.4,5
Crystallization kinetics are traditionally monitored by X-ray
powder diffraction (XRPD) and differential-scanning calorim-
etry (DSC).2 Spectroscopic methods, including nuclear
magnetic resonance9 and Raman spectroscopy (FT-Raman10
and low-frequency Raman11), are also used for quantifying
amorphous contents in solid forms. Different methods observe
the low percentages of crystalline or amorphous forms in
samples differently. For example, a sample that appears
completely amorphous when observed with XRPD might not
be Raman- or DSC-amorphous.12 Recently, fluorescence
spectroscopy has been used for monitoring the crystallization
of pure amorphous indomethacin.13 Although fluorescence
methods are mainly used for characterizing pharmaceuticals in
solutions, they have also been utilized in solid-state contexts;
the amounts of pharmaceuticals in tablet formulations have
been estimated with fluorescence spectroscopy,14−16 and
fluorescence microscopy has been used to determine the
miscibility of pharmaceutical-polymer solid dispersions.17
Fluorescence-lifetime-imaging microscopy (FLIM) is a
method that maps the spatial distributions of excited-state
lifetimes in microscopic samples. Therefore, it gives additional
information compared with confocal or fluorescence micros-
copy. The fluorescence lifetime is an intrinsic property of the
fluorescent molecule, and unlike fluorescence intensity, it does
not depend on the concentration of the fluorophore in the
sample; photobleaching; or issues related to the equipment,
such as light scattering, the excitation intensity, or the sample’s
position. FLIM does not need high excitation intensities and is
a noninvasive method; hence, it is used widely in biomedical
applications.18,19 FLIM has several advantages compared with
traditional methods for monitoring crystallization. FLIM
images show the distributions of lifetimes and fluorescence
intensities in the sample, and therefore the method combines
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the advantages of spectral techniques and imaging techniques.
As FLIM does not need high excitation intensities, it is less
likely to destroy the sample with the excitation light than, for
example, Raman spectroscopy.10 The intrinsic nature of the
fluorescence lifetime benefits quantitative analysis. Fluores-
cence lifetimes and their amplitudes are proportional to each
other, even in situations when the fluorescence intensities
might not be. For example, if the sample is moved, or the
fluorescent pharmaceutical is unevenly distributed in a
pharmaceutical product, the fluorescence intensity changes
but the lifetime stays constant.
We now present the first attempt to monitor solid-state
transformations quantitatively by fluorescence-lifetime-imaging
microscopy. Indomethacin (Figure 1a), whose solid-state forms
can be distinguished by their fluorescence,13 was chosen as a
model drug. Indomethacin is a nonsteroidal anti-inflammatory
drug (NSAID) that has several well-characterized solid forms:
the amorphous form and the α- and γ-crystalline forms.20 The
γ-form is the most stable in ambient conditions, but amorphous
indomethacin can crystallize to either of these two crystalline
forms depending on the preparation method7 and storage
conditions.4,5 We were able to identify amorphous and γ- and
α-crystalline indomethacin according to their time-resolved
fluorescences. This information was used for following the
crystallization of amorphous indomethacin upon storage. The
progress of the crystallization was seen in the FLIM images and
the fluorescence-decay curves as lifetime changes, and the decay
data was used for a quantitative analysis of crystallization.
Amorphous indomethacin was also crystallized rapidly with a
drop of ethanol. In this arrangement, the sample was not
moved between measurements. Thus, the intensities of the
FLIM images were proportional to each other, and the progress
of crystallization could be followed from the fluorescence-
lifetime distributions.
■ EXPERIMENTAL SECTION
Materials. Indomethacin (Orion Finland) was obtained in
the γ-crystalline form and used as received. The amorphous
form was obtained by melting γ-indomethacin on a glass
microscope slide or aluminum pan at 175 °C on a heating plate.
The completely melted indomethacin was cooled down at
room temperature on a metallic surface for a few minutes and
then transferred to a desiccator. Amorphous indomethacin was
stored over NaOH (0% relative humidity, RH) in a desiccator
for at least an hour before further treatment. α-Indomethacin
was prepared from γ-indomethacin dissolved in ethanol, using a
recrystallization method modified from the method used by
Kaneniwa et al.21 as follows. A saturated indomethacin ethanol
solution at 80 °C was quickly added to room temperature
water. Indomethacin crystallized immediately. The crystals were
removed by filtration and dried over NaOH in a desiccator for
at least 24 h.
The different indomethacin forms were characterized by
differential-scanning calorimetry (DSC, Mettler Toledo
DSC821e). The samples (2.7−3.5 mg) were heated from 10
to 180 °C at 10 °C min−1. The DSC results are presented in
Table 1. The melting points and enthalpies for γ- and α-
indomethacin were similar to those published in the
literature.22,23 The amorphous form showed a glass-transition
temperature around 45 °C, a crystallization exotherm, and two
endothermic melting peaks, which correspond to the melting of
α- and γ-crystalline indomethacin. The DSC results for
amorphous indomethacin are consistent with other studies.6,7,24
The calibration of the DSC equipment was checked with an
indium calibration sample.
Monitoring Crystallization. Fresh amorphous samples
were stored in a desiccator at room temperature at 0% RH
maintained by NaOH. For the simulated-storage experiment,
four fresh amorphous samples were prepared on glass
microscope slides. The intrinsic crystallization of the samples
in the storage conditions, 60 °C and 0% RH, was monitored by
FLIM for 10 days. Two of the freshly prepared samples were
measured to represent t = 0 before the samples were subjected
to the storage conditions. Because one measurement sequence
took about 1 h, two of the samples were measured after 3 h of
storage at 60 °C and 0% RH, and the two other samples were
measured after 6 h of storage. After that, three of the previous
samples were chosen and these samples were measured at every
Figure 1. (a) Molecular structure of indomethacin. (b) Normalized excitation (dashed line) and emission (solid line) spectra for different forms of
indomethacin. For the excitation spectra, the monitoring wavelengths were 460 (γ), 480 (α), and 505 nm (amorphous). Fluorescence spectra were
measured with an excitation at 340 nm. (c) Normalized fluorescence-decay curves measured by FLIM using an excitation at 405 nm. The
fluorescence was monitored at 430−900 nm wavelengths. The decays were calculated from 30 × 30 μm areas for the crystalline forms and a 15 × 15
μm area for the amorphous form. The colors are the same in (b) and (c).
Table 1. Thermal Properties for γ- and α-Crystalline Indomethacin (N = 2) and Amorphous Indomethacin (N = 3)a
form Tg (°C) Tc (°C) Tm (°C) ΔHm (J g−1 °C−1)
γ   159.75 ± 0.02 −109.30 ± 0.03
α   150.46 ± 0.09 −90 ± 3
amorphous 44.6 ± 0.6 117 ± 5 156, 161 −90 ± 5
aThe glass-transition temperature, Tg (midpoint); crystallization temperature, Tc (onset); melting temperature, Tm (onset); and melting enthalpy,
ΔHm, were measured by DSC at a heating rate of 10 °C min−1.
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time point. Three FLIM images representing the different
samples for each time point were chosen for the analysis.
Crystallization was also induced by adding a drop of ethanol
to the microscope slide and placing a fragment of amorphous
indomethacin on top of the ethanol droplet. Crystallization was
thus induced between the microscope slide and indomethacin
fragment, which enabled the imaging of the crystallizing surface
of the sample. Ethanol-induced crystallization was monitored
for 95 min. The sample was not moved between imaging points
in order to avoid external factors (e.g., the focal plane or imaged
area) affecting the fluorescence intensity.
Fluorescence Properties. The fluorescence and excitation
spectra were measured with a Fluorolog Yobin Yvon-SPEX
spectrofluorometer (Horiba Scientific) for all of the indome-
thacin forms. A solid sample was pressed between two glass
slides, and its emission was measured at a 20° angle relative to
the excitation light (front-face geometry). The monitoring
wavelengths for the excitation spectra were 505 nm (γ), 480 nm
(α), and 460 nm (amorphous). The excitation wavelength for
the emission spectra was 340 nm for all the indomethacin
forms.
The FLIM measurements were performed with a MicroTime
200 (PicoQuant) fluorescence-lifetime microscope coupled to
an inverted Olympus IX-71 (Olympus) microscope. The
samples were imaged with a 100× oil objective (numerical
aperture, NA = 1.4) or a 40× air objective (NA = 0.65). A
pulsed diode laser LDH-P-C-405 (PicoQuant) emitting at 405
nm with a 60 ps resolution was used for the fluorescence
excitation. The maximum scan area of the equipment was 80 ×
80 μm, and the spatial resolution was approximately 300 nm.
For the present samples, the estimated laser-penetration depth
was 500 nm. SymPhoTime version 4.7 software was used to
calculate the lifetime-map images. The lifetime analyses were
calculated using the whole FLIM image or smaller areas (the
regions of interest, ROIs) if the fit was clearly better for the
smaller area (for amorphous indomethacin) or if there were
regions with different lifetimes in the same image. The
fluorescence lifetimes, τi, and their amplitudes, ai, were
calculated by the iterative least-squares tail-fitting method, in
which the sums of the exponentials (eq 1) were fitted to the
experimental-decay curves.
∑= τ
=
−I t a( ) e
i
N
i
t
1
/ i
(1)
The quality of the fit was evaluated in terms of the weighted-
mean-square-deviation χ2-test. The intensity-modulated FLIM
images showed both the fluorescence-lifetimes and intensity
distributions in the image. The FLIM images without intensity
modulation showed only the lifetimes.
Kinetic Analysis from Fluorescence Data. The fluo-
rescence lifetimes and their amplitudes were first determined
for pure crystalline and amorphous samples, and these lifetimes
were used as controls for determining the crystallinities of the
stored samples. The time-resolved fluorescence of each pure
form was calculated as an average of 10 parallel FLIM images.
For the kinetic analysis, the degree of conversion, α, was
calculated by25
α = −
− ∞
a a
a a
t0
0 (2)
where a0 is the fluorescence-lifetime amplitude at t = 0, at is the
amplitude at t, and a∞ is the amplitude when the crystallization
is complete.
For the ethanol-induced crystallization, the conversion was
calculated by the changes in the lifetime distributions. The
intensity at 1.74 ns, Ia, was assumed to correspond to the
proportion of the amorphous form, and the intensity at 2.21 ns,
Ic, was assumed to correspond to that of the crystalline form.
Thus, the initial degree of conversion α′ was calculated as
α′ =
+
I
I I
c
a c (3)
The shape and intensity of the fluorescence-lifetime
distribution depends on the focal plane, sample distribution,
and imaged area. Exact reproducibility for fluorescence-lifetime
distributions is difficult, and the lifetime distributions of the
pure samples could not be used as controls. The first FLIM
image at t = 5 min was chosen to be α = 0. The ethanol had not
completely evaporated from the sample during the first few
minutes, which supports us choosing t = 5 min as the onset of
crystallization instead of t = 0. Because the crystallization was
not complete at t = 95 min, the degree of conversion at the end
of the monitoring period was estimated according to eq 2 with
the fluorescence decays extracted from the FLIM-image areas
where the conversion was clearest. α′ was normalized between
this value and 0 to obtain the degree of conversion.
■ RESULTS AND DISCUSSION
Amorphous indomethacin and α-indomethacin were prepared
from γ-indomethacin as described above in the Experimental
Section. The purities of the studied indomethacin forms were
checked via their thermal properties, and they were further
characterized spectroscopically. Both the steady-state and time-
resolved fluorescences were distinctive for each of the forms
(Table 2). The excitation and emission spectra are shown in
Figure 1b. The excitation spectra were highly overlapping for
the crystalline indomethacin forms, with an excitation
maximum at around 370 nm, and the excitation spectrum for
amorphous indomethacin was shifted to longer wavelengths,
Table 2. Fluorescence Lifetimes, τi; Amplitudes, ai; and Excitation and Emission Maximum Wavelengths, λex,max and λem,max, of
the Studied Indomethacin Formsa
form τ1 (ns) a1 τ2 (ns) a2 λex,max (nm) λem,max (nm)
γ 1.66 ± 0.02 0.93 6.2 ± 0.3 0.07 365 460
α 1.19 ± 0.01 0.97 5.2 ± 0.3 0.03 370 490
amorphous 1.07 ± 0.06 0.79 2.7 ± 0.2 0.21 395 520
aThe time-resolved fluorescence data was measured by FLIM using excitation at 405 nm and monitoring the fluorescence at 430−900 nm
wavelengths. The time-resolved fluorescence for each indomethacin form is presented as an average of 10 parallel FLIM images. The decay curves
were extracted from 30 × 30 μm areas of FLIM images for the crystalline forms and a 15 × 15 μm area for the amorphous form. Excitation maxima
were measured by monitoring wavelengths of 460 nm (γ), 480 nm (α), and 505 nm (amorphous), and fluorescence maxima were measured using
excitation at 340 nm.
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with a maximum at 395 nm. The fluorescence maximum of α-
indomethacin was red-shifted by 30 nm, and the fluorescence
maximum of amorphous indomethacin was red-shifted by 60
nm compared with that of γ-indomethacin, which were in
agreement with previous studies.13 The spectra for the
crystalline forms were narrower than that of the amorphous
form, which indicated a greater level of order. The amorphous
form exhibited more intra- and intermolecular conformational
variation and had more vibrational modes, which were seen as
the broader spectrum.
The time-resolved fluorescence properties were measured by
FLIM. All of the measured indomethacin forms showed
biexponential fluorescence decays (Figure 1c) because of the
different indomethacin isomers and hydrogen-bonding patterns
in the solid states.20,26−28 The fluorescence lifetimes, τ1 and τ2,
and their amplitudes, a1 and a2, calculated by biexponential fits,
are presented in Table 2. The shorter-lived component lasted
between 1 and 2 ns for all the indomethacin forms. The longer
lifetime was 5−6 ns for the crystalline forms and less than 3 ns
for the amorphous indomethacin. The less-ordered structure
leads to the excited states in the amorphous form decaying via
vibrational relaxation more often than those in the crystalline
forms, which shortens their lifetimes compared with those of
the crystalline counterparts. Although the indomethacin forms
could be identified by their varying lifetimes, the change in
amplitudes between the amorphous and crystalline forms was
more distinct and reliable. The amplitudes for the shorter
lifetimes were 0.93 (γ) and 0.97 (α) for the crystalline forms
and 0.79 for the amorphous form. Therefore, changes in
amplitude were used to represent the degree of crystallinity in
the sample.
The different indomethacin forms could be distinguished
from each other in the FLIM images, as seen in Figure 2. It is
important to note that the images in Figure 2 are the raw
images, and they display the average arrival time of the
fluorescence photons after the excitation pulse at each pixel.
Thus, the lifetime distributions differ somewhat from the fitted
lifetimes. However, these images also provide the best contrast
between the different forms of indomethacin and are thus
utilized to visualize the crystallization processes. The color scale
in Figure 2 visualizes the γ-crystalline form as red, the α-
crystalline as blue, and the amorphous form as green. In the
partly crystalline image in Figure 2, the γ-crystalline form
(bright red area) is clearly observed in the middle of the
surrounding amorphous indomethacin.
On the basis of these results, it was concluded that the
crystalline and amorphous forms of indomethacin could be
differentiated in the FLIM images on the basis of their
distinctive fluorescence lifetimes and amplitudes.
Crystallization during Storage. Next, the potential of the
method to follow the crystallization of indomethacin during
simulated storage conditions was investigated. This is a more
complex system than that of the pure components studied
above, as changes in storage can be fairly gradual, and detecting
low levels of crystallinity is both important and challenging. To
facilitate the detection of crystallization, crystallization was
accelerated by storing the initially amorphous samples at an
elevated temperature.
The crystallization of amorphous indomethacin at 60 °C and
0% RH was monitored for 10 days with FLIM. Thus,
amorphous indomethacin samples were stored in a rubbery
state, above their glass-transition temperature, Tg (ca. 45 °C
29).
In these conditions, indomethacin has been reported to
crystallize completely in 50 days.4 As we were interested in
detecting the early stages of crystallization, a 10 day monitoring
period was considered sufficient. The surfaces of the samples
appeared to be partially covered by a crystalline layer after 24 h
and almost completely covered after 48 h when observed via
optical microscopy (Figure 3). This rapid surface crystallization
above Tg is characteristic for γ-indomethacin crystallization.
30
During the rest of the storage period, the visual appearances of
the samples changed only slightly. When monitored with
FLIM, the changes in the samples during storage were more
distinct than when they were monitored by optical microscopy,
as seen in Figure 4. During the first few hours, the samples still
resembled fresh amorphous indomethacin. As the crystalline
Figure 2. FLIM images of γ- and α-crystalline, amorphous, and
partially crystallized amorphous indomethacin. Images were taken
using 100× magnification and oil immersion (for the pure
indomethacin forms) or 40× magnification and air immersion (for
the partially crystallized sample). The excitation wavelength was 405
nm, and the fluorescence was monitored at 430−900 nm wavelengths.
The color scale for the fluorescence lifetimes is the same in all the
images and is presented at the bottom right.
Figure 3. Optical-microscope images of the amorphous indomethacin
samples stored at 60 °C and 0% RH for 10 days. The samples were
imaged with 40× magnification and air immersion. The sizes of the
images are approximately 300 × 300 μm.
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layer started to cover the sample surfaces, the surfaces became
uneven, which was also reflected in the FLIM images. The area
of the sample in the focal plane has a higher fluorescence
intensity than the areas outside the focal plane (Figure 4a), and
the areas with low fluorescence intensities are tinged blue in the
FLIM images without intensity modulation (Figure 4b).
As the crystallization proceeded, the colors in the FLIM
images changed to be more red, which indicated longer
lifetimes. The color change was not strictly located in specific
areas, nor did it follow specific morphologies. Although the
crystalline layer covered the samples quickly, the changes in the
FLIM images were more subtle during the first few days. This
indicated that the crystalline layers covering the samples were
very thin, and the majority of the fluorescence signals in the
FLIM images originated from the amorphous material under
the crystalline layers. As the crystallization proceeded, the
thicknesses of the crystalline layers increased, and the
proportion of the fluorescence from amorphous material
decreased.
The fluorescence-decay curves extracted from the FLIM
images in Figure 4 are mixtures of the decay curves of pure
amorphous and γ-crystalline indomethacin. The fluorescence
decays of the pure forms (Figure 1c) and the lifetimes
calculated from them (Table 2) are close to each other.
Therefore, a four-exponential fit with fixed lifetimes for both
the amorphous and γ-indomethacin did not give a reasonable
result, and a biexponential fit was used instead. The obtained
fluorescence lifetimes as a function of time are presented in
Figure 5a. In the beginning, the lifetimes (τ1 = 1.03 ± 0.02 ns
and τ2 = 2.57 ± 0.04 ns) clearly corresponded to amorphous
indomethacin (Table 2).
Both τ1 and τ2 increased closer to the γ-indomethacin values
as the crystallization progressed. After 10 days, τ1 was 1.48 ±
0.05 ns, and τ2 was 5.41 ± 0.11 ns. The amplitudes of the decay
components changed during the crystallization process as well:
the amplitude of τ1 (a1) increased, and that of τ2 (a2) decreased
as the sample crystallized. At t = 0, a1 was 0.74, and after 10
days, it was 0.90. Because of the nature of the amorphous form,
the amplitude values at t = 0 differed somewhat from the values
presented in Table 2 for amorphous indomethacin. Regardless,
the freshly prepared samples were clearly amorphous at the
beginning of the monitoring period. The change in amplitude
was rapid in the beginning of the experiment and slowed down
gradually as the crystallization proceeded, describing the
progress of crystallization. The degree of conversion, α, was
calculated from a2 according to eq 2,
25 where a0 was the a2
value at t = 0 and a∞ was the a2 value determined for pure γ-
indomethacin (Table 2). The degrees of conversion at different
times during storage are presented in Figure 5b.
The crystallization of indomethacin is usually consistent with
the Johnson−Mehl−Avrami−Erofeyev−Kolmogorov (JMAEK)
model.4,5,11,13,31 This model assumes that the crystallization
process has two distinct steps, nucleation and growth, and the
conversion forms a sigmoidal curve as a function of time. The
shape of the conversion in this study is clearly not sigmoidal,
and the JMAEK-model does not describe the kinetics of the
monitored crystallization process. Hence, the present results
were fitted to several decelerating kinetic models described by
Kwaham et al.25 The best agreement with our data was
obtained with the diffusion-controlled models. In diffusion-
controlled crystallization, the rate of the reaction decreases as
the crystallized layer on the surface of a film or particle
increases. For a one-dimensional reaction model, the reaction is
assumed to occur on an infinite flat surface. In this case, the
degree of conversion is directly proportional to crystalline-layer
thickness, and the reaction model is written as
Figure 4. FLIM images (80 × 80 μm) of the amorphous indomethacin stored at 60 °C and 0% RH for 10 days. The same FLIM images are
presented with (a) and without (b) intensity modulation. The images were taken with 40× magnification and air immersion. The excitation
wavelength was 405 nm, and the fluorescence was monitored at 430−900 nm wavelengths. The color scale for the fluorescence lifetimes is the same
in all the images and is presented at the bottom right.
Figure 5. (a) Fluorescence lifetimes, τ1 and τ2, obtained from the
biexponential fits to the decay curves extracted from the FLIM images;
(b) degree of conversion, α, calculated from the amplitude of the
longer living component, a2; (c) fit to the one-dimensional diffusion-
limited reaction model (eq 4); and (d) fit to the three-dimensional
diffusion-limited reaction model (eq 5) for the amorphous
indomethacin samples stored at 60 °C and 0% RH for 10 days. N =
2 for t = 0 and N = 3 for the other time points.
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α = kt2 (4)
where k is a constant, and t is time. The three-dimensional
diffusion-controlled model is based on Fick’s first law for radial
diffusion in a sphere. The model is expressed as
α α− − − = kt1 2
3
(1 )2/3
(5)
and is known as the shrinking-core reaction model. The
shrinking-core model is based on the assumption that the
crystallizing particles are spherical and that crystallization starts
at the surface of the particle. The limiting step in both models is
the diffusion of the reagent through the production layer to the
unreacted part of the sample.
The conversion is fitted to these models, and the fits are
presented in Figure 5c,d (one-dimensional, R2 = 0.973, and
three-dimensional, R2 = 0.987, respectively). The three-
dimensional model gave the best fit, especially at the beginning
of the crystallization process. However, there is no clear
physical explanation for this result. Three-dimensional diffusion
models are found to describe heterogeneous processes such as
hydrate formation32,33 and dissolution kinetics34 but not usually
crystallization from an amorphous phase. As the samples were
single, solid amorphous pieces on microscope slides, it is
unlikely that the sample would consist of spherical crystallizing
particles. The one-dimensional crystallization model describing
the thickening of the crystalline layer on an infinite plane is
more consistent with the visual observation of the crystal-
lization process, even though the fit to this model is not quite as
good as that to the three-dimensional diffusion-controlled
model. Although the samples were stored in the 0% RH
desiccator, they were exposed to humidity regularly during
measurements. Water is known to enhance molecular mobility
and thus the crystallization rate in the amorphous form,5 so it is
possible that the model describes the reaction kinetics limited
by the diffusion of water through the crystalline layer.
The observed crystallization occurred mostly on the sample
surface, so the degree of crystallization for the whole sample
was still low at the end of the monitoring period. Some
amorphous-forming organic molecules, including indometha-
cin, are found to have different crystallizing mechanisms on the
surface and in the bulk.30,35,36 Surface crystallization is usually
faster, and even a very thin crystalline layer on an otherwise
amorphous material can affect the solubility and dissolution
properties of the product.37 In this study, we detected
crystallization on the sample surface quantitatively and were
able to follow the rate of crystalline-layer thickening.
Ethanol-Induced Crystallization. In the storage study
above, the samples were measured at different times and stored
in a desiccator between measurements. This means that the
fluorescence intensity varied slightly from one measurement to
the next. This was not an issue here and actually showed one of
the benefits of following the fluorescence lifetime instead of the
intensity. The lifetime is not dependent on the intensity.
Therefore, we did not need to pay attention to having the same
sample orientation in each measurement. However, we also
wanted to see what the results would look like if we could
follow the same spot throughout the crystallization process. For
this purpose, we needed to have faster crystallization for
practical purposes. Here, amorphous indomethacin was crystal-
lized rapidly with a drop of ethanol. The amorphous sample
dissolved partially in the ethanol, and crystallization started
from the ethanol solution (solution-mediated crystallization).
The whole imaged area was initially wetted with ethanol. In
these measurements, the sample was not moved between the
measurements, and the fluorescence intensities of the FLIM
images were proportional to each other. This meant that the
lifetime distributions presenting the average arrival-time
distributions of the photons could be used for quantitative
measurements.
In this experiment, there were two different areas present in
the FLIM images: an area where the time-resolved fluorescence
stayed almost unchanged, and an area where the fluorescence
lifetime increased. The clearest difference between these two
areas was again seen in the fluorescence-lifetime amplitudes
(Figure 6a). The time-resolved fluorescence from the stable
area was closest to that of pure α-indomethacin (τ1 = 1.15 ns, a1
= 0.96; τ2 = 3.6 ns, a2 = 0.04). It is known that crystallization in
supersaturated ethanol solutions can result in the α-form
instead of the more stable γ-form.38 At t = 5 min, the time-
resolved fluorescence extracted from the unstable area of the
FLIM image resembled that of amorphous indomethacin (τ1 =
0.69 ns, a1 = 0.78; τ2 = 2.0 ns, a2 = 0.22). In reality, the sample
consisted of indomethacin in its crystalline and amorphous
forms as well as indomethacin dissolved in ethanol. For the
analysis, this area was assumed to correspond to amorphous
indomethacin. After 95 min, the fluorescence lifetime in the
unstable area more closely resembled that of crystalline
indomethacin than that of amorphous indomethacin (Figure
6b). The fitting of the decay curves extracted from the whole
image area did not give reasonable results because of the
multiple fluorescence lifetimes present in the same FLIM
image. However, the observed fluorescence-lifetime distribution
(Figure 7a) changed uniformly as the crystallization proceeded.
With the exception of t = 5 min, the lifetime distributions
crossed each other at the isosbestic point at 1.78 ns, indicating
the existence of two species contributing to the lifetime
distributions. At t = 5 min, there was most probably still a
significant amount of indomethacin dissolved in ethanol
present in the sample, which would explain why the curve
Figure 6. (a) Fluorescence-lifetime amplitudes, a2, for the unstable and
stable areas of the FLIM images and (b) fluorescence lifetimes, τ1 and
τ2, for the unstable areas in the FLIM images as a function of time for
the ethanol-induced crystallization. The fluorescence lifetimes and
their amplitudes were obtained from a biexponential fit to the decay
curves extracted from FLIM images.
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does not go through the isosbestic point. The intensity of the
band at 1.47 ns was assumed to correspond to the amount of
amorphous indomethacin in the sample, and that of the band at
2.21 ns was assumed to correspond to that of crystalline
indomethacin. The initial degree of conversion was calculated
from the intensities of these bands according to eq 3.
Determining the onset of crystallization and the final
conversion was not possible from the fluorescence-lifetime
distributions. The actual conversion was calculated from the
initial conversion, as described in the Experimental Section. It is
presented in Figure 7b. The conversion gave a reasonable fit to
the first-order reaction model (R2 = 0.977). The fit is presented
in Figure 7c. A similar analysis was done to the fluorescence-
decay curves extracted from the unstable areas of the FLIM
images during the crystallization process, with similar results
(not presented).
To detect the fluorescence-lifetime distribution change, as in
this example, the crystallization rate of the monitored area
should be feasible for detection with the experimental
equipment. As one measurement can take up to 5 min, it is
not reasonable to try to detect the crystallization rates of the
samples that crystallize completely in 5−15 min. The maximum
scan area of our equipment was 80 × 80 μm, and in most of the
attempts to monitor the ethanol-induced crystallization, the
sample crystallized too fast in the monitored area for kinetic
analysis. This can be avoided by using FLIM equipment with a
larger scanning area or faster data acquisition. However, our
results clearly indicate that it is possible to monitor the
crystallization process using FLIM images with several
fluorescence lifetimes when the FLIM-image intensities are
proportional to each other.
■ CONCLUSIONS
We were able to identify different solid indomethacin forms
(amorphous and γ- and α-crystalline) and monitor the
crystallization of the amorphous form by fluorescence-life-
time-imaging microscopy (FLIM). According to our results,
there are two possible approaches for the kinetic analysis of
FLIM data. If the crystallization is rapid enough, and there is no
need to move the sample during crystallization, the
crystallization kinetics can be obtained from a fluorescence-
lifetime-distribution analysis. A lifetime-distribution analysis can
be used even if there are several different fluorescence lifetimes
present in the sample, as presented in this study. The second
method for kinetic analysis is to use the fluorescence-lifetime
amplitudes calculated from the decay curves for kinetic analysis.
Although the fluorescence intensity is sensitive to external
factors such as the sample orientation and focal plane,
fluorescence lifetimes and their amplitudes are unaffected, as
demonstrated during the 10 day monitoring period. This allows
the removal of the samples from the equipment between
measurements, and the same sample can be monitored
quantitatively as long as needed. In future studies, it would
be interesting to compare the FLIM method to other imaging
techniques, such as Raman, CARS, or FTIR microscopy. In
short, we have demonstrated that FLIM is a sensitive and
nondestructive method for monitoring crystallization on the
surface of a sample.
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